PTPA and hepatoblastoma: In hepatoblastoma, the PP2A activator, FTY720, was synergistic with the chemotherapeutic cisplatin, and combination therapy led to significantly decreased tumor volumes in vivo compared to either agent alone [44], suggesting a role for PP2A activation in combination with other agents.